CEBPB and metabolic syndrome: Down-regulation of C/EBPβ by MCPIP1 might be also potentially relevant to clinical applications, since enhanced expression of C/EBPβ exists in the background of pathological conditions such as, cancer and metabolic syndrome [35–37].